Health Canada drug approval and how to check a drug's status
Health Canada drug approval involves review of safety, efficacy and quality. Check the DIN, NOC and current DPD status before treating a drug as marketed.
Health Canada drug approval follows a review of a drug's safety, efficacy and quality. A favourable new-drug review results in a Notice of Compliance (NOC) and Drug Identification Number (DIN). Other drug applications can receive a DIN without an NOC. Health Canada explains these routes in its drug review overview and DIN fact sheet.
To check a particular medicine, start with the Drug Product Database (DPD). Confirm the exact product and its current recorded status, then use the NOC database to check the new-drug authorization record. An old approval record doesn't establish that a product is being sold today. The DPD status definitions distinguish authorization from marketing.
What Health Canada reviews
A drug submission contains evidence on safety and efficacy, manufacturing and quality information, and proposed labelling. Health Canada weighs the benefits against the risks before deciding whether to authorize the drug. Studies can come from Canada or elsewhere. The process does not require every medicine to repeat its studies in Canada, as the review overview explains.
The submission route matters. A New Drug Submission (NDS) must contain sufficient information to assess safety and effectiveness. That includes manufacturing controls and substantial evidence of clinical effectiveness. Filing an NDS does not guarantee approval. The new-drug requirements require a satisfactory submission and an issued, unsuspended NOC for ordinary sale or advertising.
An Abbreviated New Drug Submission (ANDS) uses a comparison-based route. Its requirements include pharmaceutical equivalence and bioequivalence to a Canadian reference product. The route of administration must be the same, and conditions of use must fall within those of the reference product. The submission still needs enough information to assess safety and effectiveness under section C.08.002.1.
For a regulatory team, matching an ingredient name alone is insufficient. The ANDS requirements concern the relationship to a Canadian reference product, not simply approval abroad. When assessing a proposed ANDS, compare the route of administration and conditions of use as well as equivalence. Keep that submission assessment separate from checking whether an existing product is authorized.
What the DIN and NOC establish
A DIN is an eight-digit number assigned by Health Canada to a drug product before marketing. Some products require both a DIN and an NOC. Others receive DIN authorization without going through the new-drug route. The DIN fact sheet makes that distinction.
These records answer different questions:
| Record | What it tells you | What to check next |
|---|---|---|
| DIN | Identifies the drug product assigned the number by Health Canada | The matching DPD record and status |
| NOC | Records authorization following satisfactory review of a new-drug submission | The relevant product and authorization, then current DPD status |
| DPD status | Describes the product's current recorded state | Whether it is approved, marketed, dormant or in another state |
The table draws on Health Canada's DIN explanation, NOC database and DPD terminology. Don't treat the existence of a DIN or historical NOC as proof of present commercial availability.
How to check whether a drug is approved by Health Canada
Use the databases together. The DPD provides product information and recorded availability, while the NOC database provides new-drug authorization information. Both are updated nightly, according to their respective landing pages.
Start with the exact DPD product
Open the Drug Product Database and locate the product you need to assess. Confirm its identity and DIN before recording a conclusion. Keep the check at product level rather than relying on an ingredient name or a different product's authorization.
Read the recorded status alongside the identifier. A database entry alone does not answer whether the product is currently marketed. Health Canada's terminology page defines these states:
- Approved means an active DIN for a reviewed product authorized for sale but not yet marketed in Canada.
- Marketed means an active DIN for a product currently being sold in Canada.
- Dormant means the product was previously marketed but has had no sales for at least 12 consecutive months.
The word "available" leaves a practical question unresolved: does it mean authorized, launched or in stock? An Approved record establishes authorization before marketing, while Marketed describes a product being sold. Neither status guarantees stock at a particular pharmacy or supply location. Use the official status definitions rather than treating those labels as synonyms.
For an internal assessment, save the product name, DIN, recorded status and date of your check together. State whether your conclusion concerns authorization or marketing. Keep the supporting database record with that conclusion so another reviewer can see what you checked. Treat any question about local supply as a separate check, rather than extending the database finding beyond what it supports.
Check the new-drug authorization record
For a new-drug authorization, consult the Notice of Compliance database. Match the record to the product and authorization under review. Keep its historical decision separate from the product's current recorded status.
A missing NOC is not, by itself, proof that a DIN-authorized product lacks authorization. Some drugs receive a DIN without an NOC. Check which route applies before drawing that conclusion, using the DIN guidance.
Read the product information
Use the product monograph or prescribing information to check authorized uses and restrictions. A product monograph is a factual, scientific document without promotional material. It describes the drug, relevant conditions of use and safety information, according to Health Canada's terminology.
Don't expect a monograph for every DIN. Drugs regulated solely under Division 1 do not require one. Many have prescribing information instead, as the DPD terminology page explains. That distinction prevents a missing monograph from becoming a false rejection of an otherwise authorized product.
Read this information for the product being checked. An authorization question and a conditions-of-use question need different evidence: the database record establishes the recorded product state, while product information describes its uses and restrictions. Keep both in view when deciding what an approval record supports.
What approval with conditions means
A Notice of Compliance with conditions (NOC/c) authorizes marketing with a condition that the sponsor undertake additional studies to verify clinical benefit. Check the particular product and indication in the NOC/c listing. It records condition-status information, including conditions met, discontinuations and suspensions, and directs readers to the DPD for product status. Don't assume conditions remain outstanding indefinitely, or describe conditional authorization as an unapproved experimental product.
Is Health Canada the Canadian FDA equivalent?
For drug authorization, Health Canada performs the role people usually mean by the “Canadian FDA equivalent.” Its name is Health Canada, not “FDA Canada.” Its Canadian review process assesses submissions for authorization in Canada.
FDA approval alone does not authorize ordinary sale in Canada. Canadian new-drug requirements still apply under section C.08.002. For a US regulatory team entering Canada, a US approval should not replace the Canadian product and authorization checks above.
International collaboration does not remove separate decisions. In the oncology collaboration Project Orbis, each participant conducts its own review and retains independence over final decisions, labelling negotiations and timelines. The FDA's Project Orbis FAQ describes that arrangement. It is not blanket mutual recognition or a promise of simultaneous approval.
RegAffairs AI has a saved answer on Health Canada drug approval and checking authorization. Health Canada's review overview also explains that safety monitoring continues after authorization.